Mucinous Adenocarcinoma Predicts Poor Response and Prognosis in Patients With Locally Advanced Rectal Cancer: A Pooled Analysis of Individual Participant Data From 3 Prospective Studies

Assessment of clinical and pathological complete response after neoadjuvant chemoradiotherapy in rectal adenocarcinoma and its therapeutic implications

“…Thus, a study that included patients with LARC (from three prospective clinical trials) assessed the predictive implication of mucinous adenocarcinoma (MAC) on the rate of pCR achievement after neoadjuvant treatment. Although in patients who received only neoadjuvant chemotherapy the rate of pCR was not significantly different between MAC group and non-MAC group (0% vs. 13.2%, respectively; p =0.11), among patients treated with neoadjuvant CRT (irrespective the chemotherapy regimen) the rate of pCR was statistical significantly higher in non-MAC group than in the MAC group (27.3% vs. 11%, respectively; p =0.03) [ 61 ].…”

Pretreatment “prognostic nutritional index” as an indicator of outcome in lung cancer patients receiving ICI-based treatment: Systematic review and meta-analysis

“…[8] More recent studies have extended the PNI to predict prognosis in additional groups of patients, such as those with gastrointestinal malignancies, gynecological tumors, and lung cancer. [9][10][11][12][13] In particular, numerous retrospective clinical studies have examined the value of pretreatment PNI in assessing the prognosis of lung cancer patients receiving ICI therapies. [14][15][16][17][18][19][20][21] The research problem of this meta-analysis was to determine the prognostic value of pretreatment PNI in lung cancer patients receiving ICI-based treatment by investigating the association between pretreatment PNI and prognosis of lung cancer patients receiving ICI-based treatment.…”

“…[8] More recent studies have extended the PNI to predict prognosis in additional groups of patients, such as those with gastrointestinal malignancies, gynecological tumors, and lung cancer. [9–13] In particular, numerous retrospective clinical studies have examined the value of pretreatment PNI in assessing the prognosis of lung cancer patients receiving ICI therapies. [14–21]…”

Colorectal mucinous adenocarcinoma indicates a meaningful subtype: A whole genome sequencing study

“…1 MAC has distinct characteristics compared with the commonest subtype, non-specific adenocarcinoma (AC), including clinicopathologic factors, molecular features, therapy response, and prognosis. [2][3][4][5] However, since the molecular mechanisms differences between the MAC and AC are still unclear, all of the current treatment guidelines rarely notice their distinction. 6,7 To illustrate these issues, we firstly performed RNAsequencing on 40 samples comprising 15 MACs, 15 ACs, and 10 normal colorectal tissues, which were collected from our central (hereinafter referred as USC set).…”

“… 1 MAC has distinct characteristics compared with the commonest subtype, non‐specific adenocarcinoma (AC), including clinicopathologic factors, molecular features, therapy response, and prognosis. 2 , 3 , 4 , 5 However, since the molecular mechanisms differences between the MAC and AC are still unclear, all of the current treatment guidelines rarely notice their distinction. 6 , 7 …”